AxoGen (NASDAQ:AXGN) Price Target Raised to $65.00

AxoGen logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Leerink Partners raised AxoGen’s price target to $65 from $56 and maintained an “outperform” rating, implying 14.39% upside from the prior close.
  • Analyst sentiment is broadly positive: 13 analysts rate AXGN a Buy, two a Hold, and one a Sell; the consensus rating is “Moderate Buy,” with a $58.67 target.
  • AxoGen reported quarterly EPS of $0.21, beating the $0.13 estimate, while revenue of $75.83 million also topped expectations of $73.45 million.
  • Interested in AxoGen? Here are five stocks we like better.

AxoGen (NASDAQ:AXGN - Get Free Report) had its price target boosted by Leerink Partners from $56.00 to $65.00 in a report released on Thursday, Benzinga reports. The brokerage presently has an "outperform" rating on the medical equipment provider's stock. Leerink Partners's price target indicates a potential upside of 14.39% from the stock's previous close.

AXGN has been the subject of a number of other reports. Barclays boosted their target price on shares of AxoGen from $50.00 to $60.00 and gave the company an "overweight" rating in a research note on Thursday, October 29th. Mizuho set a $65.00 target price on shares of AxoGen in a research report on Wednesday, October 28th. Citizens Jmp raised their target price on shares of AxoGen from $50.00 to $55.00 and gave the stock a "market outperform" rating in a research report on Thursday, July 30th. Jefferies Financial Group reaffirmed a "buy" rating and set a $60.00 price target on shares of AxoGen in a research note on Wednesday, October 28th. Finally, Citigroup reiterated a "market outperform" rating on shares of AxoGen in a report on Thursday, July 30th. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, AxoGen currently has a consensus rating of "Moderate Buy" and a consensus price target of $58.67.

Read Our Latest Stock Analysis on AXGN

AxoGen Stock Performance

Shares of AXGN traded down $0.13 during mid-day trading on Thursday, hitting $56.82. 478,109 shares of the company traded hands, compared to its average volume of 1,237,941. The company has a debt-to-equity ratio of 0.04, a quick ratio of 10.67 and a current ratio of 12.02. The stock has a 50-day moving average price of $43.78 and a two-hundred day moving average price of $40.76. AxoGen has a 1 year low of $25.16 and a 1 year high of $59.72. The stock has a market cap of $3.39 billion, a price-to-earnings ratio of -87.54 and a beta of 1.21.

AxoGen (NASDAQ:AXGN - Get Free Report) last released its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.08. The company had revenue of $75.83 million for the quarter, compared to the consensus estimate of $73.45 million. AxoGen had a negative return on equity of 5.35% and a negative net margin of 11.96%. Equities analysts anticipate that AxoGen will post -0.36 earnings per share for the current year.

Insider Activity at AxoGen

In related news, Director Joseph Tyndall sold 3,500 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $49.70, for a total value of $173,950.00. Following the transaction, the director directly owned 10,650 shares of the company's stock, valued at $529,305. This trade represents a 24.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.44% of the company's stock.

Hedge Funds Weigh In On AxoGen

Several hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of AxoGen during the 2nd quarter valued at $204,123,000. Artemis Investment Management LLP raised its position in shares of AxoGen by 27.5% during the 3rd quarter. Artemis Investment Management LLP now owns 1,780,992 shares of the medical equipment provider's stock worth $74,659,000 after purchasing an additional 384,200 shares during the period. Wellington Management Group LLP lifted its position in AxoGen by 44.3% in the 2nd quarter. Wellington Management Group LLP now owns 1,391,654 shares of the medical equipment provider's stock valued at $64,280,000 after purchasing an additional 427,089 shares during the last quarter. Stephens Investment Management Group LLC raised its stake in AxoGen by 336.8% during the 3rd quarter. Stephens Investment Management Group LLC now owns 1,130,854 shares of the medical equipment provider's stock valued at $47,405,000 after acquiring an additional 871,949 shares in the last quarter. Finally, Soleus Capital Management L.P. increased its stake in AxoGen by 1,795.3% during the 3rd quarter. Soleus Capital Management L.P. now owns 1,081,000 shares of the medical equipment provider's stock valued at $45,316,000 after buying an additional 1,023,964 shares during the period. Hedge funds and other institutional investors own 80.29% of the company's stock.

AxoGen Company Profile

(Get Free Report)

AxoGen, Inc. is a medical technology company focused on repairing peripheral nerve injuries—damage to nerves outside the brain and spinal cord. Its products are used by surgeons in procedures intended to restore nerve function and sensation. The company's offerings include Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves, and Axoguard products designed to protect, connect or cap nerves during repair. Axogen also provides education and support for healthcare professionals who use its nerve-repair solutions.

Recommended Stories

Analyst Recommendations for AxoGen (NASDAQ:AXGN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AxoGen Right Now?

Before you consider AxoGen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AxoGen wasn't on the list.

While AxoGen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines